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Introduction: Estrogen signaling is pivotal in the progression of estrogen receptor positive breast cancer primarily
by the regulation of cell survival and proliferation. Micro (mi)RNAs have been demonstrated to be regulated
by estrogen to mediate estrogenic effects. Herein, we determined the role of estrogen regulated miR-26 and its
underlying molecular mechanisms associated with estrogen receptor (ER)+ breast cancer proliferation.
Methods: The expression of miR-26a and miR-26b was evaluated by real-time quantitative (RT)-PCR. The expression
of miR-26a or miR-26b was modulated in ER+ breast cancer cells (MCF-7 and T47D) and tumor cell growth
in vitro and an in vivo xenograft model was determined. Bioinformatics analyses were utilized to screen for estrogen
responsive genes, which were also predicted to be targeted by miR-26. Luciferase reporter assays were performed
to confirm miR-26 regulation of the 3' UTR of target genes. The levels of miR-26 target genes (CHD1, GREB1
and KPNA2) were evaluated by western blotting and immunohistochemistry.
Results: Estrogen reduced the expression of miR-26a and miR-26b in ER+ breast cancer cells. Forced expression
of miR-26a or miR-26b significantly inhibited the estrogen stimulated growth of ER+ breast cancer cells and
tumor growth in xenograft models, whereas miR-26a/b depletion increased the growth of ER+ breast cancer
cells in the absence of estrogen treatment. Screening of estrogen responsive genes, which were also predicted
to be targeted by miR-26, identified GREB1 and nine other genes (AGPAT5, AMMECR1, CHD1, ERLIN1, HSPA8,
KPNA2, MREG, NARG1, and PLOD2). Further verification has identified nine genes (AGPAT5, CHD1, ERLIN1, GREB1,
HSPA8, KPNA2, MREG, NARG1 and PLOD2) which were directly targeted by miR-26 via their 3′ UTR. Functional
screening suggested only three estrogen regulated miR-26 target genes (CHD1, GREB1 and KPNA2) were involved in
the regulation of estrogen promoted cell proliferation. Depletion of either CHD1, GREB1 or KPNA2 significantly
abrogated the enhanced growth of ER+ breast cancer cells due to miR-26 depletion. We further demonstrated
that estrogen stimulated c-MYC expression was both sufficient and necessary for the diminished expression of
miR-26a and miR-26b.
Conclusions: We have identified a novel estrogen/MYC/miR-26 axis that mediates estrogen stimulated cell
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Breast cancer is the most common malignant disease in
women. However, the molecular pathogenesis of breast
cancer remains poorly defined due to its heterogeneity
[1]. Approximately 70% of human breast cancer is es-
trogen receptor (ER)-alpha-positive and estrogen sig-
naling plays a pivotal role in both the pathogenesis and
the progression of ER+ breast cancer [2]. One of patho-
logical effects of estrogen in hormone-responsive breast
cancer is to promote proliferation and tumor growth
[3]. In postmenopausal women with early-stage ER+
breast cancer, anti-estrogen therapy is utilized as an ef-
fective adjuvant treatment. However, many patients
whose tumors respond to anti-estrogen therapy even-
tually develop resistance and tumor recurrence [4]. An
improved understanding of the molecular basis of es-
trogen action and the development of new strategies to
improve the efficacy of anti-estrogens are therefore
required.
MicroRNAs (miRNAs) are noncoding RNAs that range
in size from 20 to 25 nucleotides and promote mRNA
degradation and/or inhibition of translation by base pairing
with the 3′ untranslated region (UTR) of target mRNAs
[5]. Multiple recent reports have established miRNAs as
important for the initiation, promotion and progression of
various human cancers [6,7]. miRNAs have been identified
to function in both oncogenic and tumor suppresser
roles [6,7]. The therapeutic manipulation of miRNAs
may present an attractive clinical strategy because one
miRNA could potentially regulate the coordinated ex-
pression of hundreds of different genes [8,9]. Various
recent reports have observed that miRNAs are often
deregulated in breast cancer [10,11] and that several
deregulated miRNAs (for example, let-7, miR-21, miR-
125b, miR-221 and miR-222) may possess important roles
in breast cancer progression by contributing to cell prolif-
eration, survival and metastasis [12-17]. The expression of
some miRNAs has also been demonstrated to be regulated
by estrogen in an ER-dependent manner [18-20]. The iden-
tification of the targets of estrogen-regulated miRNAs is
critical to understand function of the miRNAs and their
underlying molecular mechanisms associated with ER+
breast cancer progression.
In this study, we report that the expression of miR-26a
and miR-26b was decreased by estrogen stimulation and
that forced expression of miR-26a or miR-26b abrogated
estrogen-stimulated breast cancer cell growth both in vitro
and in vivo. CHD1, GREB1 and KPNA2 were identified
as estrogen-regulated direct targets of miR-26a/b. The ex-
pression of CHD1, GREB1 or KPNA2 was required for
estrogen-stimulated breast cancer cell growth. We further
demonstrated that estrogen-regulated c-MYC expression
was required for the suppression of miR-26a and miR-26b
levels. Methods to enhance miR-26 expression may thusbe considered as an adjuvant therapeutic strategy for pa-
tients with ER + breast cancer.
Methods
Cell culture
MCF-7, T47D, MDA-MB-231 and BT549 cells were pur-
chased from American Type Culture Collection and
were cultured in the recommended conditions. All cells
were maintained in a humidified incubator at 37°C and
5% carbon dioxide. For 17β-estradiol (E2) stimulation
experiments, cells were cultured for at least 3 days in
phenol red-free RPMI 1640 with 5% dextran-coated
charcoal-treated serum before E2 (10−8 mol/l) treatment.
Plasmid construction
To stably express miR-26a or miR-26b in MCF-7 cells,
the retroviral vector pBABE-Puro-miR-26a or pBABE-
Puro-miR-26b was constructed. The genome segment
encompassing the mature miR-26a sequence was as de-
scribed previously [21] or the 77 base pair DNA frag-
ment corresponding to pre-miR-26b was amplified from
human genomic DNA and then cloned into the pBABE-
Puro plasmid. To stably deplete miR-26a or miR-26b in
MCF-7 and T47D cells, we generated miR-26a and miR-
26b sponge elements. We introduced nine copies of
CCTATCCACCATTACTTGAA complementary sequences
to miR-26a and miR-26b, each with mismatches at positions
11 to 13 for improved stability, into pBABE-Puro expression
vector [22,23].
RNA oligonucleotides and transfection
miRNAs and small interfering RNAs (siRNAs) were synthe-
sized by GenePharma (Shanghai, China). miRNA mimics
are synthetic duplexes representing mature miRNAs. siRNA
and miRNA transfection was performed using lip2000
(QIAGEN). 20 nmol/l siRNA or miRNA was used for trans-
fection in serum-free medium. Total RNA and protein were
prepared 48 to 72 hours after transfection and further used
for quantitative polymerase chain reaction (PCR) or western
blot analysis.
Quantitative analysis of miRNAs and mRNAs
Total RNA and miRNA were extracted from cultured
cells or clinical samples of breast cancer using the miR-
Vana miRNA Isolation Kit (Ambion) according to the
manufacturer’s protocols. The TaqMan stem-loop real-
time (RT)-PCR approach was used to assess the expres-
sion of miRNAs with kits from Applied Biosystems. For
quantitative analysis of mRNA expression, 100 to 200 ng
total RNA was used for synthesis of random-primed
single-stranded cDNA using the Primescript RT reagent
kit (TaKaRa) and cDNA was subjected to quantitative
PCR using SYBR green Master MIX (Applied Biosystem).
The relative amount of gene transcripts were normalized
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dependent experiments were each performed in triplicate.
Protein extraction and western blot
Cells were lysed using cell lysis buffer (Cell Signaling)
and a protein concentration determined with the BCA
Protein Assay kit (Pierce). Equal amounts of total pro-
teins were separated in 10% SDS polyacrylamide gels
and transferred to polyvinylidene difluoride membranes
(Bio-Rad). Membranes were blocked for 1 hour with 1%
bovine serum albumin in Tris-buffered saline containing
0.05% Tween 20, incubated overnight with primary anti-
body, washed and incubated with secondary antibody, and
visualized by chemiluminescence. The antibodies used
were as follows: CHD1 (Millipore), GREB1 (Abcam),
KPNA2 (Abcam) and β-actin (Abcam).
Luciferase reporter assay
The full-length 3′ UTR of the genes were amplified and
cloned downstream of Renilla luciferase in a psiCHECK2
vector (Promega). Cells plated on 24-well plates were
transfected with 100 ng plasmid and 200 nmol/l miR-26a,
miR-26b mimics or negative control. After 48 hours, cells
were lysed and assayed with Dual Luciferase Assay (Pro-
mega) according to the manufacturer’s instructions. Three
independent experiments were performed in triplicate.
MTT assay
Cells (103 per well) were plated in 96-well plates in a
final volume of 100 μl. Twenty-four hours after plating,
10 pmol miRNA mimics, siRNAs or negative control oli-
gonucleotides were transfected into the cells with lip2000
(QIAGEN). The MTT assay was performed at 24, 48, 72
and 96 hours as described previously [24].
Tumor xenograft in nude mice
MCF-7-NC, MCF-7-miR-26a or MCF-7-miR-26b cells
(3 × 106 cells per site) were injected into the mammary
fat pad of 4-week-old BALBc nu/nu mice (Shanghai
Slaccas). Long-release E2 pellets (Innovative Research of
America) were implanted the day before inoculation.
In vivo protocol approval
Research protocols were designed and conducted in
accordance with the guidelines set by the Institutional
Animal Care and Use Committee, University of Science
and Technology of China (USTCACUC1301016).
Results
Decreased expression of miR-26 is required for estrogen-
promoted cell proliferation
We have previously screened estrogen-regulated miRNAs
using miRNA microarray profiling [17]. In addition to let-
7 g, which was downregulated by estrogen, miR-26a andmiR-26b were among other estrogen-regulated miRNAs
in ER-alpha-positive MCF-7 cells (Figure S1 in Additional
file 1). ER+MCF-7 and T47D breast cancer cells were
used to verify estrogen regulation of miR-26a and miR-
26b expression using TaqMan stem-loop RT-PCR analysis.
The miRNA expression values were normalized to U6.
The expression of miR-26a and miR-26b significantly
decreased after both 12 and 24 hours treatment with
10−8 mol/l E2 in MCF-7 and T47D cells with prior es-
trogen deprivation (Figure 1a,b).
We next determined whether miR-26a/b modulated
growth of ER+ breast cancer cells. MCF-7 and T47D
cells were thus transfected with negative control, miR-
26a mimics or miR-26b mimics. Forced expression of
miR-26a or miR-26b inhibited the estrogen-simulated in-
crease in cell viability and total cell number in MCF-7
(Figure 1c,d) and T47D cells (Figure S2 in Additional file 1)
when compared with control oligonucleotides. However,
forced expression of miR-26a or miR-26b did not signifi-
cantly affect either cell viability or total cell number in both
types of cells when cultured in estrogen-deprived conditions
(Figure 1c,d; Figure S2 in Additional file 1) compared with
control oligonucleotides. Moreover, forced expression of
miR-26a or miR-26b did not significantly affect either cell
viability or total cell number of the ER-negative MDA-MB-
231 and BT549 cell lines (Figure S2 in Additional file 1).
Hence it is apparent that forced expression of miR-26a or
miR-26b abrogated the proliferative effects of E2 in ER+
breast cancer cells.
We further constructed a miR-26a and miR-26b dual
specific sponge, namely Sponge-miR-26, to deplete both
endogenous miR-26a and miR-26b (Figure 1e) and to
determine whether reduced miR-26a/b levels were re-
quired for estrogen promotion of mammary carcinoma cell
proliferation. MCF-7-Sponge-miR-26 and T47D-Sponge-
miR-26 as well as their respective control cells (MCF-7-Vec
and T47D-Vec) were generated by forced expression of
Sponge-miR-26 or empty vector. Forced expression of
Sponge-miR-26 significantly reduced the expression of both
miR-26a and miR-26b (Figure 1f,g). miR-26 depletion in
MCF-7 and T47D cells resulted in increased cell growth
under estrogen-deprived conditions (Figure 1h,i; Figure S2
in Additional file 1). However, no significant differences in
estrogen-simulated cell viability or total cell number were
observed upon miR-26 depletion in those ER+ cells. Hence,
it is apparent that estrogen repression of miR-26 expression
is required for estrogenic effects in ER+ breast cancer cells.
miR-26 expression suppressed breast cancer growth in
nude mice
We further determined whether miRNA-26 expression
could suppress breast cancer cell growth in vivo. MCF-
7-miR-26a, MCF-7-miR-26b and cognate control cells
were injected subcutaneously into female BALB/c nude
Figure 1 miR-26 inhibits breast cancer cell growth. (a, b) Effect of 17β-estradiol (E2) on miR-26a and miR-26b expression. MCF-7 and T47D
were treated with 10 nmol/l E2 in phenol red-free medium containing 5% charcoal-stripped fetal bovine serum and microRNAs (miRNAs) from a
triplicate sample were isolated at indicated time points. The miRNA level was measured by TaqMan stem-loop quantitative real-time polymerase
chain reaction (qRT-PCR). U6 was used as an internal control. Relative expression level of (a) miR-26a and (b) miR-26b. (c) MCF-7 cells after 2 days
of E2 deprivation were transfected with NC, miR-26a or miR-26b mimics and 1 day later were seeded in six-well plates with or without 10 nmol/l
E2. At the indicated time points after transfection, cells were trypsinized and total cell numbers were counted using Trypan blue. (d) MCF-7 cells
after 2 days of E2 deprival were transfected with NC, miR-26a or miR-26b mimics and 1 day later were seeded in 96-well plates with or without
10 nmol/l E2. At 72 hours after plating, the MTT assay was performed to determine the proliferation (viability) of MCF-7 cells. (e) Sequences of mature
miR-26a/b, and one repeat of sponge. (f, g) Relative expression levels of miR-26a and miR-26b between MCF-7-Vec, MCF-7-Sponge-miR-26 or T47D-Vec,
T47D-Sponge-miR-26 were measured by TaqMan stem-loop qRT-PCR. (h) MCF-7-Vec and MCF-7-Sponge-miR-26 cells after 3 days of E2 deprivation were
seeded in six-well plates with or without 10 nmol/l E2. At the indicated time points, MCF-7-Vec and MCF-7-Sponge-miR-26 cells were trypsinized and
total cell numbers were counted using Trypan blue. (i) MCF-7-Vec and MCF-7-Sponge-miR-26 cells after 3 days of E2 deprivation were
seeded in 96-well plates with or without 10 nmol/l E2. At 96 hours after plating, the MTT assay was performed to determine the proliferation
of MCF-7-Vec and MCF-7-Sponge-miR-26 cells. *P < 0.05. **P < 0.01.
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tation. Inoculation of MCF-7-miR-26a or MCF-7-miR-
26b cells resulted in the formation of slower growing
and significantly smaller tumors compared with tumors
derived from MCF-7-NC inoculated mice (Figure 2a).
The miR-26a and miR-26b expression levels were
quantified in tumors derived from MCF-7-miR-26a
or MCF-7-miR-26b cells (Figure 2b,c). A significantly
lower proportion of proliferative Ki67+ tumor cells
were observed by immunohistochemical analysis in
tumor sections derived from MCF-7-miR-26a orMCF-7-miR-26b cells compared with the control cells
(Figure 2d).
Identification of targets of miR-26 involved in
estrogen-promoted cell growth
To identify downstream targets of miR-26, we performed
bioinformatics analysis using three algorithms that pre-
dict the mRNA targets of a particular miRNA: TargetS-
can, PicTar and miRanda. A total of 695 putative target
genes of miR-26 were predicted by at least one of the
three algorithms (Figure 3a). Four independent gene
Figure 2 miR-26 inhibits breast tumor growth in vivo. (a) MCF-7-NC, MCF-7-miR-26a and MCF-7-miR-26b cells mixed with matrigel were
transplanted into the mammary fat pad of immunodeficient mice supplemented with 17β-estradiol (E2), and tumor sizes were measured
every 4 days until day 27 and the tumors were harvested. (b, c) The relative expression levels of miR-26a/b between tumors derived from MCF-7-NC
and tumors generated from MCF-7-miR-26a respectively were quantified by TaqMan stem-loop quantitative real-time polymerase chain reaction. U6
was used as an internal control. (d) Tumors derived from MCF-7-miR-26a/b cells showed a lower level of Ki-67 protein than tumors derived from
MCF-7-NC cells. (e) Immunohistochemistry analysis of GREB1, CHD1 and KPNA2 expression for tumor sections. *P < 0.05. **P < 0.01.
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genes in MCF-7 cells were also employed for screening
estrogen-regulated genes. A total of 403 genes were up-
regulated in E2-treated MCF-7 cells compared with the
control cells. The overlap between the putative target
genes of miR-26 and E2-upregulated genes yielded a set
of 26 genes, which were considered as candidate target
genes utilized by miR-26 to mediate estrogen-stimulated
cellular effects.
To determine which of the 26 genes could be actually
regulated by miR-26, RT-PCR analysis was performed toexamine their expression with forced expression of
miR-26b in MCF-7 or T47D cells. The mRNA levels of
10 genes (AGPAT5, AMMECR1, CHD1, ERLIN1, GREB1,
HSPA8, KPNA2, MREG, NARG1 and PLOD2) signifi-
cantly decreased following the forced expression of miR-
26b (Figure 3b; Figure S3 in Additional file 1). Moreover,
we further verified that the expression of the 10 genes at
the mRNA level was upregulated following estrogen
treatment (Figure S4 in Additional file 1), suggesting
that those 10 genes could be regulated by both estrogen
and miR-26.
Figure 3 Regulation of gene expression by miR-26. (a) Venn diagram showing the number of genes identified by prediction methods
compared with differential expression in 17β-estradiol (E2)-treated MCF-7 cells. (b) Ectopic expression of miR-26b in MCF-7 cells decreased mRNA
levels of the indicated 10 genes by quantitative real-time polymerase chain reaction. Glyceraldehyde 3-phosphate dehydrogenase was used as an
internal control. (c) Luciferase reporter assays in T47D cells, with co-transfection of the wild-type 3′ utranslated region (UTR) and miRNA as indicated.
(d) Luciferase reporter assays in T47D cells, with co-transfection of wild-type 3′ UTR and miRNA sponge as indicated. *P < 0.05. **P < 0.01.
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erated fusions to a luciferase reporter gene. Forced ex-
pression of miR-26a or miR-26b mimics significantly
reduced the activity of luciferase reporter gene fused to
the 3′ UTR of all the candidate target genes (except
AMMECR1) by more than 40% (Figure 3c). These data
suggest that miR-26a and miR-26b could directly target
nine genes via their respective 3′ UTR. Consistently,
depletion of miR-26a/b by miR-26 sponge could increase
the activity of luciferase reporter genes fused to the 3′
UTR of the same cohort of nine genes (AGPAT5, CHD1,
ERLIN1, GREB1, HSPA8, KPNA2, MREG, NARG1 and
PLOD2) by more than 30% (Figure 3d). The activity of a
luciferase reporter gene containing the AMMECR1 3′
UTR exhibited minimal change upon depletion of en-
dogenous miR-26 (Figure 3d).
CHD1, GREB1 and KPNA2 as critical mediators of miR-26
elicited cell growth
Given that miR-26 negatively regulated ER+ breast can-
cer cell proliferation, we wished to determine which of
the identified targets of miR-26 actually mediated miR-
26-influenced cell growth. MCF-7 and T47D cells were
thus transfected with siRNAs against these nine genesand the efficacy of siRNAs verified by RT-PCR (Figure
S5 in Additional file 1). Interestingly silencing of CHD1,
GREB1 or KPNA2 but not the remainder of the miR-26-
regulated target genes significantly decreased E2-promoted
growth of MCF-7 and T47D cells (Figure 4). In addition,
silencing of the other six genes did not significantly affect
the growth of MCF-7 and T47D cells in the presence or
absence of estrogen (Figure S6 in Additional file 1), sug-
gesting that the regulation of AGPAT5, ERLIN1, HSPA8,
MREG, NARG1 or PLOD2 by miR-26a and miR-26b may
be used for other cellular functions in breast cancer cells.
CHD1, GREB1 and KPNA2 are the direct targets of miR-26
Using TargetScan, we located the potential binding sites
for miR-26 at the 3′ UTR of CHD1, GREB1 and KPNA2
and the respective mutants were further constructed
(Figure 5a). We co-transfected luciferase reporter plas-
mids containing the 3′ UTR of each of the three genes
with or without mutation and miR-26a mimics, miR-26b
mimics or control oligonucleotides. Forced expression of
miR-26a mimics or miR-26b mimics markedly reduced
the activity of luciferase reporter genes fused to wild-
type 3′ UTRs by more than 40%, but failed to affect the
reporter activity when the 3′ UTR was mutated (Figure 5b).
Figure 4 Small interfering RNA-mediated depletion of CHD1, GREB1 or KPNA2 expression recapitulates the tumor suppressive functions
of miR-26. (a, c) MCF-7 or T47D cells deprived of estrogen for 2 days were infected with NC or small interfering RNA (siRNA) and 1 day later were
seeded in six-well plates with or without 10 nmol/l 17β-estradiol (E2). At the indicated time points after transfection, cells were trypsinized and
total cell numbers were counted using Trypan blue. (b, d) MCF-7 or T47D cells deprived of estrogen for 2 days were infected with NC or siRNA
and 1 day later were seeded in 96-well plates with or without 10 nmol/l E2. At 72 hours after plating, the MTT assay was performed to determine
the proliferation of MCF-7 and T47D cells. *P < 0.05. **P < 0.01.
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marked increase in the luciferase activity of the reporter
plasmid containing the wild-type 3′ UTRs, but not their
mutants (Figure 5c). miR-26 hence directly binds to the re-
spective 3′ UTR of CHD1, GREB1 or KPNA2 to regulate
their expression. We further verified that forced expression
of miR-26a mimics or miR-26b mimics significantly re-
duced the expression of CHD1, GREB1 and KPNA2 at the
protein level in MCF-7 and T47D cells (Figure 5d). As
expected, the expression of CHD1, GREB1 and KPNA2
protein was increased after forced expression of Sponge-
miR-26 in both MCF-7 and T47D cells (Figure 5e). Trans-
fection of miR-26a or miR-26b mimics substantially
abrogated estrogen-stimulated expression of CHD1, GREB1
and KPNA2, indicating that estrogen induced expression of
CHD1, GREB1 and KPNA2 via miR-26a/b (Figure 5f,g).
Immunohistochemical analysis of the tumors derived from
MCF-7 cells with forced expression of miR-26 demon-
strated lower expression of GREB1, CHD1 and KPNA2
compared with control tumors (Figure 2e).CHD1, GREB1 and KPNA2 as mediators of cell growth
promoted by miR-26 depletion
To further determine whether the expression of CHD1,
GREB1 or KPNA2 was required for cellular events down-
stream of miR-26a/b, siRNAs for CHD1, GREB1 or KPNA2
were transfected into MCF-7/Vec, MCF-7/Sponge-miR-26,
T47D/Vec and T47D/Sponge-miR-26 cells (Figure 6). The
results showed that specific depletion of CHD1 or GREB1
or KPNA2 by siRNA significantly abrogated the enhanced
growth of MCF-7 (Figure 6a,b) and T47D (Figure 6c,d)
cells consequent to miR-26 depletion. The expression of
CHD1, GREB1 and KPNA2 is hence required to promote
cell growth consequent to miR-26 depletion.
Estrogen-induced c-MYC expression is necessary for the
repression of miR-26a and miR-26b expression
c-MYC was previously reported to regulate the expres-
sion of many miRNAs, including miR-26a and miR-26b
[21,29,30]. To explore whether c-MYC was required for
estrogen-simulated repression of miR-26a/b in MCF-7
Figure 5 miR-26 directly targets CHD1, GREB1 and KPNA2 genes. (a) Putative miR-26-binding sequences in the 3′ untranslated region (UTR)
of CHD1, GREB1 and KPNA2 mRNA. Mutations were generated on the CHD1, GREB1 and KPNA2 3′ UTR sequence in the complementary site for
the seed region of miR-26. (b) Luciferase reporter assays in T47D cells, with co-transfection of wild-type (wt) or mutant (mut) 3′ UTR and
microRNA (miRNA) as indicated. (c) Luciferase reporter assays in T47D cells, with co-transfection of wt or mut 3′ UTR and miRNA sponge as
indicated. (d) Forced expression of miR-26a or miR-26b in MCF-7 and T47D cells decreased protein levels of CHD1, GREB1 and KPNA2 by
western blot analysis. (d, e) After forced expression or depletion of miR-26, the expression of CHD1, GREB1 and KPNA2 protein were analyzed by
western blot assay. (f, g) Western blotting analysis of the expression of CHD1, GREB1 and KPNA2 protein in 17β-estradiol (E2)-treated MCF-7 and T47D
cells transfected with the indicated miRNA molecules. *P < 0.01.
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plasmids were transfected in both cell lines. As expected,
forced expression of c-MYC resulted in the reduced ex-
pression of miR-26a and miR-26b in both MCF-7 and
T47D cells (Figure 7a,b,c). c-MYC has been reported as
an estrogen-responsive gene and is a positive regulator
of estrogen-stimulated breast cancer cell growth [31-33].
We therefore next determined whether c-MYC was in-
volved in estrogenic suppression of miR-26a/b. We firstverified the efficacy of the c-MYC-specific siRNA duplex
in the presence or absence of estrogen stimulation in
both MCF-7 and T47D cells (Figure 7d). Abrogation of
MYC expression by siRNA resulted in a substantial in-
creased expression of estrogen-stimulated miR-26a and
miR-26b (Figure 7e,f ), indicating that c-MYC was a me-
diator of estrogenic repression of miR-26a/b expression.
We next investigated whether c-MYC expression was re-
quired for estrogen-stimulated expression of GREB1,
Figure 6 CHD1, GREB1 or KPNA2 small interfering RNA partially mimics the effect of Sponge-miR-26 on MCF-7 and T47D cells.
(a, c) MCF-7-Vec and MCF-7-Sponge-miR-26 cells deprived of estrogen for 2 days were transfected with NC or small interfering (siRNA)
and 1 day later were seeded in six-well plates without 10 nmol/l 17β-estradiol (E2). At the indicated time points after transfected NC or
siRNA, MCF-7-Vec, MCF-7-Sponge-miR-26, T47D-Vec and T47D-Sponge-miR-26 cells were trypsinized and total cell numbers were counted using Trypan
blue. (b, d) MCF-7-Vec and MCF-7-Sponge-miR-26 cells deprived of estrogen for 2 days were transfected with NC or siRNA and 1 day later
were seeded in 96-well plates without 10 nmol/l E2. At 96 hours after plating, the MTT assay was performed to determine the proliferation
of MCF-7-Vec, MCF-7-Sponge-miR-26, T47D-Vec and T47D-Sponge-miR-26 cells. *P < 0.05. **P < 0.01.
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siRNA significantly diminished estrogen-stimulated ex-
pression of GREB1, CHD1 and KPNA2 in both MCF-7
and T47D cells (Figure 7g,h).
miR-26a and miR-26b expression are decreased in breast
cancer
We compared the levels of miR-26a/b in 20 samples of
normal breast tissue and 30 ER+ breast cancer specimensby stem-loop qRT-PCR. Expression of miR-26a and miR-
26b was reduced in breast cancer specimens (P < 0.05)
compared with normal tissues (Figure 8a,b). We further
evaluated the expression levels of CHD1, GREB1 and
KPNA2 mRNA in these breast cancer specimens by qRT-
PCR. The results showed that the average expression
levels of CHD1 and KPNA2 were significantly higher in
breast cancers (P < 0.05) than in normal breast tissues
(Figure 8c,d). However, the average expression level of
Figure 7 c-MYC is required for 17β-estradiol repression of miR-26 expression. (a) Expression of endogenous c-MYC protein in MCF-7 and
T47D cells transfected with pcDNA3.1-Vec of pcDNA3.1-c-MYC. TaqMan stem-loop quantitative real-time polymerase chain reaction (qRT-PCR) analysis
of the expression of miR-26a (b) and miR-26b (c) in MCF-7 and T47D cells after forced expression of c-MYC. (d) Expression of endogenous c-MYC protein
in 17β-estradiol (E2)-treated MCF-7 and T47D cells transfected with small interfering RNA (siRNA) control or siMYC. TaqMan stem-loop qRT-PCR analysis of
the expression of miR-26a (e) and miR-26b (f) in E2-treated MCF-7 and T47D cells transfected with the indicated c-MYC siRNA. U6 was used as an internal
control. (g) Expression of endogenous CHD1, GREB1, KPNA2 and c-MYC protein in E2-treated MCF-7 cells transfected with siRNA control or siMYC.
(h) Expression of endogenous CHD1, GREB1, KPNA2 and c-MYC protein in E2-treated T47D cells transfected with siRNA control or siMYC. β-ACTIN
was used as input control. (i) A model of estrogen promotion of c-MYC expression, which suppressed miR-26a and miR-26b and resulted in increased
expression of CHD1, GREB1 and KPNA2 and subsequent enhanced cell growth. **P < 0.01.
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in normal breast tissues (Figure S7 in Additional file 1).
We subsequently correlated CHD1, GREB1 and KPNA2
with miR-26 expression in these specimens. When CHD1
mRNA levels were plotted against miR-26a and miR-
26b expression, significant inverse correlations were
observed (P < 0.05; Figure 8e,f ). When KPNA2 mRNA
levels were plotted against miR-26b expression, signifi-
cant inverse correlations were observed (P < 0.05; Figure 8h).
However, when the KPNA2 mRNA level was plotted against
miR-26a expression (P > 0.05, Figure 8g) or when the
GREB1 mRNA level was plotted against miR-26 ex-
pression (P > 0.05; Figure S7 in Additional file 1), there
were no significant inverse correlations.Discussion
Breast cancer is one of the most prevalent causes of cancer-
related death for women worldwide. Estrogens play an im-
portant role in breast cancer [2,3]. Estrogen acts through
ER-alpha and ER-beta, and blockade of estrogen signaling
with anti-estrogens is an effective treatment for the
majority of patients with ER-alpha-positive breast cancer.
However, many ER+ breast cancer patients that initially
respond to anti-estrogen therapy develop tumor recurrence
[4]. An improved understanding of the molecular basis of
estrogen treatment and the development of new strategies
to increase the efficacy of anti-estrogens are required.
miRNAs have been demonstrated to play important
roles in breast cancer development [5,6]. miR-26a or
Figure 8 miR-26 was downregulated in breast cancer and inversely correlated with CHD1 and KPNA2 levels. (a, b) Relative expression
levels of miR-26 in human breast specimens. MicroRNA (miRNA) levels were measured by TaqMan stem-loop quantitative real-time polymerase
chain reaction. U6 was used as an internal control. (c, d) Relative expression levels of CHD1 and KPNA2 mRNA in breast clinical specimens. CHD1
and KPNA2 abundance was normalized to glyceraldehyde 3-phosphate dehydrogenase. (e, f, g, h) A statistically inverse correlation between
miR-26 and CHD1 and KPNA2 mRNA levels in human breast specimens (Spearman’s correlation analysis).
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cer and they were therefore regarded as tumor suppressor
miRNAs [18,19,23,34]. Estrogen treatment resulted in re-
duced expression of miR-26a in an ER-dependent manner
[18,19]. miR-26a has also been reported to directly sup-
press progesterone receptor expression through binding to
the progesterone receptor 3′ UTR. However, whether pro-
gesterone receptor actually mediated miR-26a repression-
promoted cell growth in response to estrogen stimulation
was not defined in this study [18]. Herein, we report that
miR-26a and miR-26b were downregulated following estro-
gen treatment in ER+ human breast cancer cells. To date,
experimentally validated miR-26 targets contain many on-
cogenes, including EZH2 [30], CCND2 [21], CCNE2 [21],
MTDH [34] and SLC7A11 [35]. However, none of these
were reported to be estrogen responsive.
To determine how the altered expression of miR-26 may
mediate estrogenic effects, we first screened estrogen-responsive genes that were also predicted to be miR-26 tar-
get genes by both bioinformatics and RT-PCR analysis.
GREB1 and nine other genes (AGPAT5, AMMECR1,
CHD1, ERLIN1, HSPA8, KPNA2, MREG, NARG1 and
PLOD2) were subsequently identified. Further verifica-
tion by luciferase reporter assay identified nine other
genes (AGPAT5, CHD1, ERLIN1, GREB1, HSPA8, KPNA2,
MREG, NARG1 and PLOD2) that were directly targeted
by miR-26 via their 3′ UTR. Functional screening sug-
gested that only three estrogen-regulated miR-26 target
genes (CHD1, GREB1 and KPNA2) were involved in the
regulation of estrogen-promoted cell proliferation. We
thus identified CHD1, GREB1 and KPNA2 as novel func-
tional targets of miR-26. The expression of miR-26a and
miR-26b in human breast cancer cells suppressed cell
growth, at least partly through repression of CHD1,
GREB1 and KPNA2. Consistently, depletion of CHD1,
GREB1 or KPNA2 produced cell growth inhibition similar
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ation. These data verified previous findings, in which the
depletion of GREB1 suppressed MCF-7 cell proliferation
[25]. However, we further determined that increased ex-
pression of CHD1, GREB1 and KPNA2 following estrogen
treatment was partially due to the decreased expres-
sion of miR-26a and miR-26b. Moreover, we deter-
mined that CHD1 and KPNA2 were necessary for
estrogen-stimulated proliferation of breast cancer cells.
c-MYC, as a well-known estrogen-responsive gene, has
been shown to mediate the proliferative effects of estrogen
in ER+ breast cancer cells [36]. Antisense oligonucleotides
directed against c-MYC inhibit estrogen-induced cell pro-
liferation in a manner similar to that of anti-estrogens
[37]. In this study, we examined the possibility of the es-
trogenic effects of c-MYC mediating a c-MYC-regulated
miRNA network. c-MYC has been reported to suppress
the expression of many miRNAs, including miR-26a and
26b [21,29,30]. However, it was unclear whether c-MYC is
involved in estrogenic repression of miR-26a and miR-26b
expression. Our observations imply that c-MYC is neces-
sary for inhibition of miR-26a and miR-26b expression
produced by estrogen. The results further suggest that ab-
errant c-MYC expression, which is frequently observed in
human breast cancers [38], can contribute to the estro-
genic effect by alteration of miR-26a and miR-26b expres-
sion. Our results have thus identified a novel pathway by
which estrogen utilizes c-MYC for suppression of miR-
26a/b to promote the expression of CHD1, GREB1 and
KPNA2 (Figure 7i).
This study systematically investigated the functionality
and mechanism of miR-26a and miR-26b in estrogen-
promoted ER+ breast cancer cell proliferation. GREB1,
CHD1 and KPNA2 were identified as novel targets of
miR-26a/b and were demonstrated to be necessary for
estrogen-promoted ER+ breast cancer cell proliferation.
Further, we demonstrated that estrogen-stimulated c-MYC
expression was both sufficient and necessary for the dimin-
ished expression of miR-26a and miR-26b. These findings
will facilitate a better understanding of the molecular
pathogenesis of breast cancer and suggest that mimics of
miR-26a and miR-26b may be considered as a novel strat-
egy for breast cancer therapy.
Conclusions
Estrogen signaling is pivotal in the progression of ER+
breast cancer. An improved understanding of the molecu-
lar basis of estrogen action and the development of new
strategies to improve the efficacy of anti-estrogens are re-
quired. We have therefore identified a novel estrogen/
MYC/miR-26 axis that mediated estrogen stimulated cell
growth via CHD1, GREB1 and KPNA2 and suggest that
upregulation of miR-26a and miR-26b may be considered
as novel strategy for breast cancer therapy.Additional file
Additional file 1: contains the following additional data. Figure S1
shows a heat-map of 10 miRNAs differentially expressed between MCF7/
estrogen-deprived and MCF7/estrogen-treated cells. Figure S2 shows
miR-26-inhibited breast cancer cell growth: (a) total cell number of T47D
was counted; (b) MTT assay was performed to determine the proliferation
of T47D cells; (c) T47D-Vec and T47D-Sponge-miR-26 cells were trypsinized
and total cell number was counted; (d) MTT assay was performed to
determine the proliferation of T47D-Vec and T47D-Sponge-miR-26
cells; (e, f) MDA-MB-231 and BT549 cells were transfected with NC,
miR-26a or miR-26b mimics and total cell number was counted; (g, h)
MTT assay was performed to determine the proliferation of MDA-MB-231
and BT549 cells. Figure S3 shows regulation of gene expression by miR-26:
ectopic expression of miR-26b in T47D cells decreased mRNA levels of the
indicated 26 genes. Figure S4 shows promotion of gene expression by E2:
(a) MCF-7 and (b) T47D cells were treated with 10 nmol/l E2 and mRNAs
were isolated; mRNA level measured by qRT-PCR. Figure S5 shows efficacy
and specificity of siRNA duplexes: ectopic expression of siRNA in MCF-7 cells
decreased mRNA levels of the indicated 10 genes by qRT-PCR. Figure S6
shows that siRNA-mediated depletion of AGPAT5, ERLIN1, HSPA8, MREG,
NARG1 or PLOD2 expression was required for the tumor suppressor
functions of miR-26: (a, c) MCF-7 or T47D cells deprived of estrogen
for 2 days were transfected with NC or siRNA, and total cell number
was counted; (b, d) MCF-7 or T47D cells deprived of estrogen for
2 days were infected with NC or siRNA, and MTT assay was performed
to determine the cell proliferation. Figure S7 shows (a) relative expression
level of GREB1 in breast human specimens and (b, c) a statistical correlation
between miR-26 and GREB1 mRNA levels in human breast specimens
(Spearman’s correlation analysis). *P < 0.05. **P < 0.01.
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